Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease

• Main Authors: Melany Worbes-Cerezo, Beenish Nafees, Andrew Lloyd, Katy Gallop, Imran Ladha, Cicely Kerr
• Format: Article
• Language: English
• Published: Columbia Data Analytics, LLC
• Series: Journal of Health Economics and Outcomes Research
• Online Access: http://jheor.scholasticahq.com/article/9685-disutility-study-for-adult-patients-with-moderate-to-severe-crohn-s-disease.pdf

**Background:** Crohn’s disease (CD) treatments and associated adverse events (AEs) can be burdensome for patients. However, specific values which quantify the impact on health-related quality of life (HRQL) for economic evaluation are lacking. **Objectives:** This study aimed to elicit health utility values for AEs related to biologic treatment and surgical complications for CD in the UK. **Methods:** Health states were developed by literature review and interviews with CD patients (n=6) and gastroenterologists (n=3). Draft health states were validated in cognitive debrief interviews with patients (n=4) and gastroenterologists (n=2). Treatment AEs were described with moderate severe CD (reference state) and included hypersensitivity, injection site reactions, serious infection, lymphoma, and tuberculosis. Surgical complications were described following bowel surgery (reference state) and included anastomotic leak, wound infection, prolonged ileus/bowel obstruction, and intra-abdominal abscess. Health states were valued by 100 members of the general public who completed background questions, EQ-5D-3L, visual analogue scale rating task and time trade-off (TTO) interviews. **Results:** The mean TTO value for reference states ‘moderate to severe CD’ and ‘bowel surgery’ were 0.70 (SD=0.28) and 0.69 (SD=0.28). Participants rated lymphoma as the worst AE/surgical complication state (0.44, SD=0.37), followed by tuberculosis (0.47, SD=0.85) and anastomotic leak (0.48, SD=0.38). Values of other AE/surgical complication states ranged from 0.76 (hypersensitivity) to 0.56 (intra-abdominal abscess). **Conclusions:** This study provides utility estimates for AE and surgical complication health states not previously assessed in the context of CD. As new treatments are emerging, it is important to include these influences on quality of life in any economic evaluation of treatments.